- BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarter
- BELBUCA total prescriptions experienced its largest quarter over quarter increase since launch
Conference Call And Webcast Scheduled For 4:30 PM ET Today
RALEIGH, N.C., Nov. 08, 2018 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today reported record financial results for the third quarter ending September 30, 2018, as well as the following operational and performance highlights:
Third Quarter Operational Highlights Include
- Achieved strong BELBUCA® revenue performance with sales increasing to $12.4 million, up 92% YOY and 27% versus prior quarter
- Sustained robust BELBUCA prescription growth achieving a new high of 44,180 TRxs, up 95% versus prior year and 25% versus prior quarter. The quarterly increase of 8,690 scripts versus prior quarter was the highest for the product since launch
- Secured expanded market access for Belbuca to an additional 25 million lives, bringing the total population with preferred coverage to more than 75 million covered lives
- Successfully began implementing its four point Belbuca strategic plan for sustained growth, including expanding the sales organization by more than 30% and starting to build the new medical team
- Strengthened the executive leadership team with appointment of James Vollins as Company General Counsel, Chief Compliance Officer and Corporate Secretary
“I am very pleased by the results achieved during the third quarter across the organization,” stated Herm Cukier, CEO of BDSI. “Our continued focus on commercial execution enabled us to achieve very robust growth for BELBUCA and created a sizeable foundation to further build shareholder value for the long term. We also started implementing our previously announced four point BELBUCA strategic plan during the quarter, and were thrilled to strengthen our leadership team with the hiring of our new General Counsel. These elements of growth momentum and continued progress put us in a strong position to finish the year strong and build for future success.”
With the performance achieved through the first three quarters, and a strong balance sheet supporting the execution of the BELBUCA growth plan, the company is expecting total year 2018 financial performance for BELBUCA and total Company net revenue to be in the upper end of previous guidance.
Third Quarter 2018 Financial Results
Total Net Revenue. Total net revenue for the third quarter ended September 30, 2018, was $14.2 million, an increase of 16% compared to $12.2 million in the second quarter of 2018, and an increase of 26% compared to $11.3 million in the third quarter of 2017.
BELBUCA® Net Revenue. BELBUCA net revenue in the third quarter ended September 30, 2018, was $12.4 million, an increase of 27% compared to second quarter 2018 revenue of $9.7 million, and an increase of 92% compared to third quarter 2017 revenue of $6.4 million.
Total Operating Expenses. Total operating expenses for the third quarter ended September 30, 2018, were $14.2 million, compared to second quarter 2018 expenses of $14.9 million, and third quarter 2017 expenses of $16.9 million.
Non-GAAP Net Loss for the third quarter of 2018 was $6.4 million or ($0.10) per share, compared to second quarter 2018 net loss of $9.8 million, or ($0.16) per diluted share, and a third quarter 2017 net loss of $12.0 million, or ($0.21) per diluted share.
GAAP Net Loss for the third quarter ended September 30, 2018 was $18.9 million, or ($0.29) per basic and diluted share, including a one-time non-cash charge of $12.5 million for the beneficial conversion feature of the Series B Preferred Stock.
Cash Position. At September 30, 2018, BDSI had cash and cash equivalents of approximately $49.5 million.
Conference Call & Webcast Details
BioDelivery Sciences will host a conference call and audio webcast today, November 8, 2018 at 4:30 p.m. ET to present third quarter 2018 results and provide a business update. Dial-in details are as follows:
| Domestic: | 800-479-1004 | |
| International: | 323-794-2599 | |
| Passcode: | 9394131 | |
| Webcast: | http://public.viavid.com/index.php?id=131852 | |
| Replays available through November 22, 2018 | ||
| Domestic: | 844-512-2921 | |
| International: | 412-317-6671 | |
| Conference ID: | 9394131 | |
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI’s headquarters is in Raleigh, North Carolina.
For more information, please visit or follow us:
| Internet: | www.bdsi.com |
| Facebook: | Facebook.com/BioDeliverySI |
| Twitter: | @BioDeliverySI |
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.BELBUCA.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentation described herein, and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI’s management and are subject to significant risks and uncertainties, including those detailed in the BDSI’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the continued growth in revenue and Belbuca prescription, and the implementation and success of our Belbuca strategic plan) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI’s control). BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.
© 2018 BioDelivery Sciences International, Inc. All rights reserved.
Contacts
Mary Coleman
Vice President, Investor Relations
BioDelivery Sciences International, Inc.
919-582-9050
mcoleman@bdsi.com
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (U.S. dollars, in thousands, except share and per share amounts) | ||||||
| (Unaudited) | ||||||
| September 30, |
December 31, |
|||||
| 2018 | 2017 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 49,482 | $ | 21,195 | ||
| Accounts receivable | 12,568 | 8,852 | ||||
| Inventory | 5,434 | 6,091 | ||||
| Prepaid expenses and other current assets | 4,155 | 3,610 | ||||
| Total current assets | 71,639 | 39,748 | ||||
| Property and equipment, net | 3,170 | 3,778 | ||||
| Goodwill | 2,715 | 2,715 | ||||
| BELBUCA license and distribution rights, net | 37,125 | 40,500 | ||||
| Other intangible assets, net | 867 | 1,360 | ||||
| Total assets | $ | 115,516 | $ | 88,101 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable and accrued liabilities | $ | 23,919 | $ | 26,149 | ||
| Total current liabilities | 23,919 | 26,149 | ||||
| Notes payable, net | 50,516 | 47,660 | ||||
| Other long-term liabilities | 5,511 | 5,415 | ||||
| Total liabilities | 79,946 | 79,224 | ||||
| Commitments and contingencies | ||||||
| Stockholders’ equity: | ||||||
| Preferred Stock, 5,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock. $.001 par value, 2,093,155 shares outstanding at both September 30, 2018 and December 31, 2017, respectively; Series B Non-Voting Convertible Preferred Stock, $.001 par value, 3,100 and 0 shares outstanding at September 30, 2018 and December 31, 2017, respectively. | 2 | 2 | ||||
| Common Stock, $.001 par value; 125,000,000 and 75,000,000 shares authorized at September 30, 2018 and December 31, 2017, respectively; 70,598,687 and 55,904,072 shares issued;70,583,196 and 55,888,581 shares outstanding at September 30, 2018 and December 31, 2017, respectively. | 71 | 56 | ||||
| Additional paid-in capital | 379,824 | 313,922 | ||||
| Treasury stock, at cost, 15,491 shares | (47 | ) | (47 | ) | ||
| Accumulated deficit | (344,280 | ) | (305,056 | ) | ||
| Total stockholders’ equity | 35,570 | 8,877 | ||||
| Total liabilities and stockholders’ equity | $ | 115,516 | $ | 88,101 | ||
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
| (U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) | |||||||||||||
| (Unaudited) | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||
| Revenues: | |||||||||||||
| Product sales | $ | 13,763 | $ | 8,118 | $ | 34,367 | $ | 23,798 | |||||
| Product royalty revenues | 370 | 1,409 | 2,197 | 3,682 | |||||||||
| Research and development reimbursements | – | 532 | – | 799 | |||||||||
| Contract revenue | 23 | 1,194 | 1,047 | 21,194 | |||||||||
| Total Revenues: | 14,156 | 11,253 | 37,611 | 49,473 | |||||||||
| Cost of sales | 3,779 | 4,445 | 11,760 | 14,261 | |||||||||
| Expenses: | |||||||||||||
| Research and development: | 699 | 1,986 | 4,038 | 6,246 | |||||||||
| Sales, general and administrative | 13,489 | 14,867 | 41,013 | 44,094 | |||||||||
| Total Expenses: | 14,188 | 16,853 | 45,051 | 50,340 | |||||||||
| Loss from operations | (3,811 | ) | (10,045 | ) | (19,200 | ) | (15,128 | ) | |||||
| Interest expense | (2,567 | ) | (1,893 | ) | (7,598 | ) | (6,657 | ) | |||||
| Other expense, net | (2 | ) | (13 | ) | (8 | ) | (28 | ) | |||||
| Bargain purchase gain | – | – | – | 27,336 | |||||||||
| (Loss) income before income taxes | $ | (6,380 | ) | $ | (11,951 | ) | $ | (26,806 | ) | $ | 5,523 | ||
| Income tax benefit | – | – | (53 | ) | 15,972 | ||||||||
| Net (loss) income | $ | (6,380 | ) | $ | (11,951 | ) | $ | (26,859 | ) | $ | 21,495 | ||
| Beneficial conversion feature of convertible preferred stock | (12,500 | ) | – | (12,500 | ) | – | |||||||
| Net (loss) income attributable to common stockholders | $ | (18,880 | ) | $ | (11,951 | ) | $ | (39,359 | ) | $ | 21,495 | ||
| Basic: | |||||||||||||
| Basic (loss) income per share: | $ | (0.29 | ) | $ | (0.21 | ) | $ | (0.65 | ) | $ | 0.39 | ||
| Weighted average common stock shares outstanding: | 64,900,007 | 55,604,708 | 60,599,456 | 55,170,569 | |||||||||
| Diluted: | |||||||||||||
| Diluted (loss) income per share: | $ | (0.29 | ) | $ | (0.21 | ) | $ | (0.65 | ) | $ | 0.38 | ||
| Weighted average common stock shares outstanding: | 64,900,007 | 55,604,708 | 60,599,456 | 56,204,358 | |||||||||
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (U.S. DOLLARS, IN THOUSANDS) | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2018 | 2017 | |||||||
| Operating activities: | ||||||||
| Net (loss) income | $ | (26,859 | ) | $ | 21,495 | |||
| Depreciation | 685 | 465 | ||||||
| Accretion of debt discount and loan costs | 2,953 | 1,941 | ||||||
| Amortization of intangible assets | 3,868 | 4,103 | ||||||
| Impairment loss on equipment | 78 | – | ||||||
| Provision for inventory obsolescence | 396 | – | ||||||
| Stock-based compensation expense | 4,896 | 10,223 | ||||||
| Deferred income taxes | – | (15,972 | ) | |||||
| Bargain purchase gain | – | (27,336 | ) | |||||
| Changes in assets and liabilities, net of effect of acquisition: | ||||||||
| Accounts receivable | (3,581 | ) | (7,222 | ) | ||||
| Inventories | 261 | 2,314 | ||||||
| Prepaid expenses and other assets | (545 | ) | 1,826 | |||||
| Accounts payable and accrued expenses | (427 | ) | 8,998 | |||||
| Deferred Revenue | – | (21,716 | ) | |||||
| Net cash flows from operating activities | (18,275 | ) | (20,881 | ) | ||||
| Investing activities: | ||||||||
| BELBUCA acquisition | (1,951 | ) | (3,902 | ) | ||||
| Purchase of equipment | (155 | ) | (5 | ) | ||||
| Net cash flows from investing activities | (2,106 | ) | (3,907 | ) | ||||
| Financing activities: | ||||||||
| Proceeds from issuance of Series B preferred stock | 50,000 | – | ||||||
| Equity financing costs | (1,410 | ) | – | |||||
| Proceeds from notes payable | – | 45,000 | ||||||
| Proceeds from exercise of stock options | 528 | 313 | ||||||
| Payment of notes payable | – | (30,000 | ) | |||||
| Payment of deferred financing fees | (450 | ) | (2,798 | ) | ||||
| Net cash flows from financing activities | 48,668 | 12,515 | ||||||
| Net change in cash and cash equivalents | 28,287 | (12,273 | ) | |||||
| Cash and cash equivalents at beginning of year | 21,195 | 32,019 | ||||||
| Cash and cash equivalents at end of year | $ | 49,482 | $ | 19,746 | ||||
| Cash paid for interest | $ | 4,645 | $ | 3,816 | ||||
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | |||||||||||||
| (U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) | |||||||||||||
| (Unaudited) | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||
| Basic: | |||||||||||||
| Net (loss) income under GAAP | $ | (18,880 | ) | $ | (11,951 | ) | $ | (39,359 | ) | $ | 21,495 | ||
| Adjustment to beneficial conversion feature of convertible preferred stock | 12,500 | – | 12,500 | – | |||||||||
| Net (loss) income attributable to common stockholders’ Non-GAAP | (6,380 | ) | (11,951 | ) | (26,859 | ) | 21,495 | ||||||
| Weighted average common stock shares outstanding: | 64,900,007 | 55,604,708 | 60,599,456 | 55,170,569 | |||||||||
| Basic (loss) income per common share | $ | (0.10 | ) | $ | (0.21 | ) | $ | (0.44 | ) | $ | 0.39 | ||
| Diluted: | |||||||||||||
| Net (loss) income under GAAP | $ | (18,880 | ) | $ | (11,951 | ) | $ | (39,359 | ) | $ | 21,495 | ||
| Adjustment to beneficial conversion feature of convertible preferred stock | 12,500 | – | 12,500 | – | |||||||||
| Net (loss) income attributable to common stockholders’ Non-GAAP | (6,380 | ) | (11,951 | ) | (26,859 | ) | 21,495 | ||||||
| Weighted average common stock shares outstanding: | 64,900,007 | 55,604,708 | 60,599,456 | 55,170,569 | |||||||||
| Effect of dilutive options and warrants | – | – | – | 1,033,789 | |||||||||
| Diluted weighted average common shares outstanding | 64,900,007 | 55,604,708 | 60,599,456 | 56,204,358 | |||||||||
| Diluted (loss) income per common share | $ | (0.10 | ) | $ | (0.21 | ) | $ | (0.44 | ) | $ | 0.38 | ||
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||
| Diluted EPS under GAAP | $ | (0.29 | ) | $ | (0.21 | ) | $ | (0.65 | ) | $ | 0.38 | |
| Diluted EPS adjustment to beneficial conversion feature of convertible preferred stock | 0.19 | – | 0.21 | – | ||||||||
| Diluted EPS Non-GAAP | $ | (0.10 | ) | $ | (0.21 | ) | $ | (0.44 | ) | $ | 0.38 | |